cariprazine

Details

Generic Name:

cariprazine

Project Status:

Pending

Therapeutic Area:

Schizophrenia

Manufacturer:

AbbVie Corporation

Call for patient/clinician input open:

November 8, 2023

Brand Name:

Vraylar

Project Line:

Reimbursement Review

Project Number:

SR0827-000

Call for patient/clinician input closed:

January 8, 2024

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

For the treatment of schizophrenia in adults.

Submission Type:

Resubmission

Fee Schedule:

Pending

Indications:

For the treatment of schizophrenia in adults.

Anticipated Date:

December 20, 2023

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Last Updated : November 8, 2023